The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Harlem Globetrotters legend Haynes has been hailed as "a pioneer" who helped "set the tone for modern basketball", following his death.
The British public have voted St Paul's Cathedral the country's favourite building ahead of Stonehenge and Buckingham Palace.
A service to remember 'Operation Dynamo', the code name for the mass evacuation of allied troops in 1940, will take place on the beach.